The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib (WJOG 8114LTR).
 
Kohei Otsubo
No Relationships to Disclose
 
Hiroaki Akamatsu
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yasuhiro Koh
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Illumina; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Raindance Technologies
Consulting or Advisory Role - Tosoh Corporation
Research Funding - Chugai Pharma; Daiichi Sankyo; Novartis
 
Satoshi Morita
Honoraria - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst)
 
Daichi Fujimoto
No Relationships to Disclose
 
Akihiro Bessho
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen; AstraZeneca; Bayer Yakuhin; Kyorin; Ono Pharmaceutical; Pfizer; Taisho Toyama Pharma
 
Koichi Azuma
No Relationships to Disclose
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EPS Holdings; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Showa Yakuhin Kako; SymBio Pharmaceuticals
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Fujifilm; Janssen; Kyorin; Kyowa Hakko Kirin; Lilly Japan; M3; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; MSD; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Research Funding - AC Medical; AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Hakko Kirin; Maruho; Meiji Seika Kaisha; MSD; Nippon Boehringer Ingelheim; Ono Pharmaceutical; PAREXEL; Pfizer; Quintiles; Shionogi; Taiho Pharmaceutical